注册 | 登录| 会员列表 | 搜索 | 投稿 | 留言本  
设为首页
加入收藏
当前位置: 首页 >> 生物产业 >> 美国发布“生物技术监管协调框架2017最新修改版”
白宮發佈「生物技術監管協調框架2017年最新修改版」

作者:     来源:國際農業生物技術週報     发表时间:2017-02-10     浏览次数:     字号:    

 

白宮發佈了生物技術監管協調框2017年最新修改版2017 Update),它全面闡述了三個主要監管機構美國環境保護署(EPA)、美國食品藥品管理局(FDA)和美國農業部(USDA)在監管生物技術產品中的作用和職責。

 

 

 

使生物技術產品監管系統現代化的國家戰略一同發佈於20169月,2017 Update提供了一個靈活健全的監管系統,將為所有現代生物技術產品提供適當的監督。

為了幫助產品開發人員和公眾理解產品的監管過程,2017 Update以多種形式闡述了機構的角色和職責,包括:

    用圖形概述了機構的監管作用

    用案例分析演示了一個產品開發者如何操縱監管框架

    用一個綜合表格總結了EPAFDAUSDA在生物技術產品試驗監管中當前的職責和相關協調措施

 

引用来源:國際農業生物技術週報 (2017-01-18)

 

附件:英文摘要

 

Increasing the Transparency, Coordination, and Predictability of the Biotechnology Regulatory System

JANUARY 4, 2017 AT 1:20 PM ET BY ROBBIE BARBERO, JAMES KIM, TED BOLING, AND JULIA DOHERTY

Summary: 

EPA, FDA, and USDA release the final version of a 2017 update to the Coordinated Framework for the Regulation of Biotechnology.

In 2015, the Administration initiated an effort to modernize the regulatory system for biotechnology products by asking the Environmental Protection Agency (EPA), the Food and Drug Administration (FDA), and the United States Department of Agriculture (USDA) to accomplish three tasks:

·         clarify the current roles and responsibilities of the EPA, FDA, and USDA in the regulatory process;

·         develop a long-term strategy to ensure that the Federal regulatory system is equipped to efficiently assess the risks, if any, of the future products of biotechnology; and

·         commission an expert analysis of the future landscape of biotechnology products.

(Learn about this effort on the White House website herehere, and here or by visiting EPAFDA, and USDA.)

 

1. Clarifying current roles and responsibilities

Today’s release of the 2017 update to the Coordinated Framework for the Regulation of Biotechnology represents the first time in 30 years that the Federal government has produced a comprehensive summary of the roles and responsibilities of the three principal regulatory agencies with respect to regulating biotechnology products. This update and the accompanying National Strategy for Modernizing the Regulatory System for Biotechnology Products(Strategy) offer the public a complete picture of a robust and flexible regulatory structure that provides appropriate oversight for all products of modern biotechnology. Within that regulatory structure the Federal agencies maintain high standards that, based on the best available science, protect health and the environment, while also establishing transparent, coordinated, predictable and efficient regulatory practices. This update was completed after reviewing the public comments submitted in response to the proposed update to the Coordinated Frameworkthat was released on September 22, 2016. A brief summary of those comments, along with additional information that addresses the comments that asked for clarification on current regulation of biotechnology products, is included in the final version released today.

In order to help product developers and the public understand what the regulatory pathway for products might look like, this 2017 update to the Coordinated Framework presents information about agency roles and responsibilities in several forms, including:

·         graphics that illustrate agency-specific overviews of regulatory roles;

·         case studies that demonstrate how a product developer might navigate the regulatory framework, and;

·         a comprehensive table that summarizes the current responsibilities and the relevant coordination across EPA, FDA, and USDA for the regulatory oversight of an array of biotechnology product areas.

 

2. The long-term strategy

The Strategy, which was released in September 2016, sets forth a vision for ensuring that the Federal regulatory system is equipped to assess efficiently the risks, if any, associated with future products of biotechnology while supporting innovation, protecting health and the environment, maintaining public confidence in the regulatory process, increasing transparency and predictability, and reducing unnecessary costs and burdens. In the Strategy, the Federal agencies demonstrate their sustained commitment to ensure the safety of future products of biotechnology, increase public confidence in the regulatory system, and prevent unnecessary barriers to future innovation and competitiveness.

 

3. The future landscape of biotechnology products

Early in 2016, EPA, FDA, and USDA commissioned an independent study by the National Academy of Sciences (NAS) on future biotechnology products. The study, which is ongoing, will identify (1) major advances and potential new types of biotechnology products over the next five to ten years, (2) potential future products that might pose a different type of risk relative to existing products and organisms, (3) areas in which the risks or lack of risk relating to biotechnology are well understood, and (4) the scientific capabilities, tools, and expertise that may be useful to the regulatory agencies as they oversee potential future products of biotechnology.

Moving forward

While today’s release of the of the 2017 update to the Coordinated Framework for the Regulation of Biotechnology represents remarkable progress by the EPA, FDA, and USDA to modernize the regulatory system for biotechnology products, much work remains. The findings by the NAS report on future biotechnology products, along with the comments submitted in response to the proposed update to the Coordinated Framework and information gathered during the three public engagement sessions that EPAFDA, and USDA hosted in 2016, will be considered by these agencies in order to inform ongoing and future agency activities.

Moving forward, EPA, FDA, and USDA will continue to fulfill the goals identified in the Strategy and these agencies look forward to continued engagement from key stakeholders, such as companies, universities and research institutes, trade associations, scientific societies, foundations, consumer organizations, non-profits, and individual citizens.

 

Robbie Barbero is Assistant Director for Biological Innovation at the White House Office of Science and Technology Policy.

Ted Boling is the Associate Director for the National Environmental Policy Act at the White House Council on Environmental Quality

Julia Doherty is the Senior Director, Agricultural and SPS Affairs in the Office of the U.S. Trade Representative.

James Kim is a toxicologist in the Office of Information and Regulatory Affairs at the Office of Management and Budget.


 

责任编辑:traveler
相关链接
  • 英国出台战略计划推动生物经济...
  • 生物经济发展研究中心成员访问...
  • 安徽半汤生物经济实验区隆重召...
  • 芬兰生物经济战略与政策及其启示
  • 2017可持续农业与生物经济国际...
  • 美国发布“生物技术监管协调框...
  • 北欧推出蓝色生物经济路线图
  • 欧盟生物经济观测平台的成功实践
  • 发表评论  打印本文  推荐本文  加入收藏  返回顶部  关闭窗口
  • 上一篇: 国家《“十三五”生物产业发展规划》正式发布
  • 下一篇: 2017可持续农业与生物经济国际大会
  •    发表评论 更多评论>>
       发表评论
    姓名: QQ:
    性别: MSN:
    E-mail: 主页:
    评分: 1 2 3 4 5
    评论内容:
    验证码:
      
  • 请遵守《互联网电子公告服务管理规定》及中华人民共和国其他各项有关法律法规。
  • 严禁发表危害国家安全、损害国家利益、破坏民族团结、破坏国家宗教政策、破坏社会稳定、侮辱、诽谤、教唆、淫秽等内容的评论 。
  • 用户需对自己在使用本站服务过程中的行为承担法律责任(直接或间接导致的)。
  • 本站管理员有权保留或删除评论内容。
  • 评论内容只代表网友个人观点,与本网站立场无关。
  • ·关于我们 ·联系方式 ·人才招聘 ·网站地图 ·法律声明
    版权所有:生物经济发展研究中心 Copyright (C): The Research Center for Bioeconomy Development (RCBED)
    本网站为公益性学术网站,文中观点只代表作者个人观点,不代表本网站观点。请遵守《互联网电子公告服务管理规定》及中华人民共和国其他各项有关法律法规。